These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37797284)

  • 1. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
    Lewis KL; Jakobsen LH; Villa D; Smedby KE; Savage KJ; Eyre TA; Cwynarski K; Bishton MJ; Fox CP; Hawkes EA; Maurer MJ; El-Galaly TC; Cheah CY;
    J Clin Oncol; 2023 Dec; 41(35):5376-5387. PubMed ID: 37797284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
    Wilson MR; Eyre TA; Kirkwood AA; Wong Doo N; Soussain C; Choquet S; Martinez-Calle N; Preston G; Ahearne M; Schorb E; Moles-Moreau MP; Ku M; Rusconi C; Khwaja J; Narkhede M; Lewis KL; Calimeri T; Durot E; Renaud L; Øvlisen AK; McIlroy G; Ebsworth TJ; Elliot J; Santarsieri A; Ricard L; Shah N; Liu Q; Zayac AS; Vassallo F; Lebras L; Roulin L; Lombion N; Manos K; Fernandez R; Hamad N; Lopez-Garcia A; O'Mahony D; Gounder P; Forgeard N; Lees C; Agbetiafa K; Strüßmann T; Htut TW; Clavert A; Scott H; Guidetti A; Barlow BR; Tchernonog E; Smith J; Miall F; Fox CP; Cheah CY; El Galaly TC; Ferreri AJM; Cwynarski K; McKay P
    Blood; 2022 Apr; 139(16):2499-2511. PubMed ID: 34995350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis.
    Lee K; Yoon DH; Hong JY; Kim S; Lee K; Kang EH; Huh J; Park CS; Lee SW; Suh C
    Int J Hematol; 2019 Jul; 110(1):86-94. PubMed ID: 31115880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
    Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
    Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse.
    Akimoto M; Miyazaki T; Takahashi H; Saigusa Y; Takeda T; Hibino Y; Tokunaga M; Ohashi T; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Matsumoto K; Hashimoto C; Fujimaki K; Fujita H; Sakai R; Fujisawa S; Nakajima H
    Int J Hematol; 2024 Feb; 119(2):164-172. PubMed ID: 38233702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
    Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
    Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
    Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
    Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis.
    Jeong H; Cho H; Kim H; Chae H; Lee JB; Lee K; Kim S; Lee SW; Ryu JS; Kim KW; Chae EJ; Huh J; Park CS; Yoon DH; Suh C
    Blood Adv; 2021 Apr; 5(8):2142-2152. PubMed ID: 33881464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.
    Chamberlain MC; Johnston SK
    Neuro Oncol; 2010 Jul; 12(7):736-44. PubMed ID: 20511181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
    Wilson MR; Eyre TA; Martinez-Calle N; Ahearne M; Parsons KE; Preston G; Khwaja J; Schofield J; Elliot J; Mula Kh A; Shah N; Cheung CK; Timmins MA; Creasey T; Linton K; Smith J; Fox CP; Miall F; Cwynarski K; McKay P
    Blood Adv; 2020 Aug; 4(15):3586-3593. PubMed ID: 32761231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
    Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
    Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
    DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
    J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study.
    Hino C; Lacy C; Brothers J; Cao H; Mirshahidi H; Park K; Akhtari M
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):764-771. PubMed ID: 37482525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
    Bennett R; Ruskova A; Coomarasamy C; Theakston E; Berkahn L; Jackson S; Christophers M; Wong S; Issa S
    Am J Hematol; 2023 Jul; 98(7):1070-1079. PubMed ID: 37161765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era.
    Zhang N; Xu D; Liu B; Shi X; Xie X; Wang Z
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109299. PubMed ID: 36252471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
    Orellana-Noia VM; Reed DR; McCook AA; Sen JM; Barlow CM; Malecek MK; Watkins M; Kahl BS; Spinner MA; Advani R; Voorhees TJ; Snow A; Grover NS; Ayers A; Romancik J; Liu Y; Huntington SF; Chavez JC; Saeed H; Lazaryan A; Raghunathan V; Spurgeon SE; Ollila TA; Del Prete C; Olszewski A; Ayers EC; Landsburg DJ; Echalier B; Lee J; Kamdar M; Caimi PF; Fu T; Liu J; David KA; Alharthy H; Law J; Karmali R; Shah H; Stephens DM; Major A; Rojek AE; Smith SM; Yellala A; Kallam A; Nakhoda S; Khan N; Sohail MA; Hill BT; Barrett-Campbell O; Lansigan F; Switchenko J; Cohen J; Portell CA
    Blood; 2022 Jan; 139(3):413-423. PubMed ID: 34570876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
    Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
    Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
    Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
    Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
    Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
    Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.